Sage Journals: Discover world-class research

Abstract

Objectives

The aim of this study was to analyze the roles of miR-143 and miR-145, as well as the gene and protein expression of their targets (KRAS, ERK5, MAP3K3, and MAP4K4) in the pathogenesis of benign prostatic hyperplasia (BPH).

Methods

We analyzed the specimens of 44 patients diagnosed with BPH who underwent surgical treatment. The control group consisted of prostate samples from 2 young patients who were organ donors. miRNAs and their target genes were assessed using real-time polymerase chain reaction (qRT-PCR), and protein levels were assessed by Western blotting.

Results

miR-143 and miR-145 were overexpressed in, respectively, 62.5% and 73.8% of the cases. The ERK5 and MAP4K4 genes were underexpressed respectively in 59.4% and 100% of the BPH samples, whereas KRAS and MAP3K3 were overexpressed respectively in 79.4% and 61.5% of the samples. Increased protein expression was found for both KRAS (4,312.2 luminance/area) and MAP3K3 (7,461.7 luminance/area), while the ERK5 protein was more abundant in the samples from patients with prostate larger than 60 grams (p=0.019).

Conclusions

The overexpression of miR-143 and miR-145 in BPH samples suggests an association with the pathogenesis of the disease; additionally, the latter miRNA may act through the inhibition of MAP4K4. KRAS and MAP3K3 overexpression may also be associated with BPH pathogenesis. Further analyses are necessary to confirm these results.

Introduction

Benign prostatic hyperplasia (BPH) is one of the most common urologic diseases among elderly men (1) and is characterized by a marked stromal and acinar proliferation, which results in the occurrence of lower urinary tract symptoms (LUTS) (2) that may affect the quality of life of the patients (3). BPH pathogenesis has not been fully elucidated. Despite the well-established role of aging, hormonal factors, and genetic predisposition, the molecular and cellular mechanisms involving the stromal and epithelial components of the prostate that lead to BPH remain unclear (4).

MicroRNAs (miRNA) are a group of small RNA molecules of between 19 and 25 nucleotides that have a fundamental action in regulating the expression of genes in plants and animals (5). miRNAs are involved in a number of cellular processes, including apoptosis, differentiation, cell proliferation, and development (6-7-8). Additionally, the aberrant expression of these small RNAs has been linked to human diseases.

miR-143 and miR-145 play a fundamental role in the differentiation and proliferation of smooth muscle cells, with the ability to control the quiescent versus proliferative phenotype (9). These miRNAs appear also to have a key role in the development and differentiation of cardiac muscle and skeletal remodeling in response to tissue injury (10). miR-143 targets the genes KRAS and ERK5, and miR-145 targets the MAP3K3 and MAP4K4 genes (11).

The actions of miR-143, miR-145, and their target genes in prostate smooth muscle tissue have not been described. Therefore, the objectives of this study were to use tissue samples from patients with BPH to: (i) analyze the expression of miR-143 and its target genes (KRAS and ERK5), as well as the protein products of these genes; (ii) perform the same analyses for miR-145 and its target genes (MAP3K3 and MAP4K4). Additionally, we evaluated the correlation between the expression of these microRNAs, genes, and proteins and the important clinical parameters of this disease.

Materials and Methods

Patients

We analyzed the specimens from 44 patients diagnosed with BPH who were surgically treated by transurethral resection of the prostate or open prostatectomy at the Hospital das Clinicas of University of Sao Paulo Medical School. The exclusion criteria were previous prostatic surgery, pelvic radiotherapy, prostate cancer, and the use of 5-alpha reductase inhibitors. The control group included prostate fragments (of the transition zone) from 2 young patients who were organ donors (mean age, 30 years). All subjects provided informed consent to participate in the study and to allow the genetical analysis of their biological samples. Approval for the study was given by the institutional board of ethics (no. 0258/10).

Surgical specimens were collected immediately after surgery. A fragment of 1 cm² was sectioned from the transition zone of the prostate and stored at -80°C. The samples were used for the analysis of miRNA expression, as well as target genes' and proteins' expression. We analyzed miR-143 and miR-145, as well as their target genes KRAS, ERK5, MAP3K3, and MAP4K4 and their corresponding proteins. The miRNAs and target genes were assessed using qRT-PCR, while proteins were assessed by Western blotting.

The expression levels were compared between the study group and the 2 controls. The patients were also categorized into groups according to selected clinical parameters (Tab. I): we considered the serum levels of preoperative PSA (≤4 ng/mL or >4 ng/mL), the use of a urinary catheter, the prostate volume (≤60 g or >60 g), and age (≤65 years and >65 years).

Table I

PATIENT CHARACTERISTICS

	Patients (n=44)
Age (years)
Mean	66
Min - max	46 - 88
PSA (ng/mL)
Mean	4.7
Min - max	0.1-30.2
Bladder catheter
Yes	21 (47%)
No	23 (53%)
Prostate volume (grams)
Mean	67
Min - max	24-200

Isolation of RNA and miRNA

We used the mirVana kit (Ambion, Austin, TX) for RNA and miRNA extraction; cDNA was obtained using the TaqMan miRNA Reverse Transcription kit (Applied Biosystems, Foster City, CA) for miRNA and the High-Capacity cDNA Reverse Transcription kit for RNA according to the manufacturer's recommendations. An amount of 10 ng of miRNA was subjected to miR-143 and miR-145 sequence-specific primer stem-loop reverse transcription. The PCR reaction for obtaining cDNA from miRNA was performed using Veriti equipment (Applied Biosystem, Foster City, CA) according to the following parameters: 30 minutes at 16°C, 30 minutes at 42°C, and 5 minutes at 85°C. The same equipment was used to obtain cDNA from RNA with the following parameters: 10 minutes at 25°C, 120 minutes at 37°C, and 5 minutes at 85°C.

Analysis of gene expression

The miRNA and RNA expression levels were analyzed by qRT-PCR using an ABI 7500 Fast Real-Time PCR System (Applied Biosystems). The target sequences were amplified in a 10-μL reaction containing 5 μL TaqMan Universal PCR Master Mix, 0.5 μL TaqMan Gene Expression Assays (primers and probes; Tab. II), 1 μL cDNA, and 3.5 μL DNase-free water. The PCR cycling conditions were: 2 minutes at 50°C, 10 minutes at 95°C, and 40 cycles of 15 seconds at 95°C and 1 min at 60°C. All reactions were performed in duplicate and TaqMan B2M and RNU 43 were utilized, respectively, as the endogenous controls for gene and miRNA expression.

Table II

PRIMERS USED FOR QUANTIFYING THE EXPRESSION OF miRNA-143 AND miRNA-145 AND THEIR TARGET GENES IN BPH

Gene	Assay
miR-143	466
miR-145	467
RNU43	1095
ERK5	Hs00964718_m1
KRAS	Hs01025520_m1
MAP3K3	Hs00176747_m1
MAP4K4	Hs00377415_m1
B2M	Hs99999907_m1

We used the ΔΔCT method to calculate the relative expression of the miRNA and target genes using the formula ΔΔCT = (CT target gene/BPH sample - CT endogenous control/BPH sample) — (CT target gene/control sample - CT endogenous control/control sample). The fold change in gene expression was calculated as 2^−ΔΔCT.

Western blotting

For this analysis we used specimens from 38 of the 44 patients. The control group was represented by the same samples used for gene expression. The samples were macerated using TissueLyser (Qiagen®) equipment with RIPA lysis buffer (Lysis Buffer, Millipore) containing protease and phosphatase inhibitors. The samples were centrifuged for 20 minutes at 15,000 rpm and 4°C. The supernatant was collected and mixed with sample buffer in a 1:1 ratio. The protein samples at a concentration of 100 ng/mL were loaded onto 12% acrylamide gels (Bio-Rad; Mini-Protean TGX) and subjected to electrophoresis. The proteins were transferred to polyvinylidene fluoride (PVDF) membranes at 300 mA for 2 hours. Antibody incubation was performed using the SNAP apparatus (SNAP id system — Millipore). Each membrane was blocked with 1% bovine serum albumin (BSA, Sigma) diluted in Tris-buffered saline-Tween 20 (TBS-T) for 15 seconds. The following primary antibodies were diluted in BSA, as suggested by the manufacturer: anti-ERK5 (1:1000, Upstate), anti-KRAS (1:500; Abnova), anti-MAP3K3 (1:1000, Upstate), and anti-MAP4K4 (1:500; Abnova). The membranes were incubated for 10 minutes at room temperature, followed by incubation with the secondary antibody. We used an antibody against β-actin (1:500, Millipore) to normalize the protein loading. Lastly, the blots were subjected to detection using the Alliance 4.7 device (Uvitec Cambridge). A quantitative analysis was performed using Alliance 16.06 software.

Statistical Analysis

A statistical analysis was performed using the SPSS 19.0 software. For the comparison of gene, miRNA, and protein expression with clinical variables, we used the Student's t-test for homogeneous variables and the Mann-Whitney U test for non-homogeneous variables. For all statistical analyses we considered a level of significance of 5% (p<0.05).

Results

Analysis of miR-143 and the ERK5 and KRAS genes revealed that miR-143 was overexpressed in 62.5% of the cases (mean of 3.6-fold) and KRAS in 79.4% of the cases (mean of 2.4-fold), whereas ERK5 was underexpressed in 59.4% of the cases (mean of 0.8-fold) in hyperplastic tissues compared to normal prostate tissues (Fig. 1).

Fig. 1

Expression profile of miR-143 and KRAS and ERK5 genes in 44 patients with BPH using qRT-PCR.

In the same analysis, miR-145 was found to be overexpressed in 73.8% of the cases (mean of 3.9-fold), and MAP3K3 in 61.5% of the cases (mean of 1.2-fold); in contrast, MAP4K4 was underexpressed in 100% of the hyperplastic tissues compared to normal prostate tissue (mean expression of 0.1-fold) (Fig. 2). We found no statistical correlations when comparing the expression of miR-143, miR-145 and the ERK5, KRAS, MAP3K3, and MAP4K4 genes with clinical parameters (data not shown).

Fig. 2

Expression profile of miR-145 and MAP3K3 and MAP4K4 genes in 44 patients with BPH using qRT-PCR.

The analysis of the proteins encoded by the ERK5, KRAS, MAP3K3, and MAP4K4 genes is shown in Figure 3. We found a strong expression of the MAP3K3 and KRAS proteins after normalization to the β-actin levels (Tab. III).

Fig. 3

KRAS, MAP3K3, ERK5, MAP4K4, and β-actin proteins in BPH and normal tissue samples. The HeLa cell line was used as a positive control for KRAS and ERK5, while the 3T3/A31 cell line was used for MAP3K3 and MAP4K4.

Table III

ERK5, KRAS, MAP3K3, AND MAP4K4 PROTEIN EXPRESSION IN BPH AND CONTROLS BY WESTERN BLOTTING

Western Blot	ERK5	KRAS	MAP3K3	MAP4K4	β-actin
Mean (BPH)	3240.8	4312.2	7461.7	2827.3	5752.9
Mean (normal prostate)	3619.4	1397.1	2726.2	4103.6	5601.5

The only statistically significant correlation between ERK5, KRAS, MAP3K3, and MAP4K4 protein expression with clinical parameters was found for ERK5, which was more highly expressed in patients with a prostate greater than 60 grams (p=0.019).

Discussion

Discovered almost 20 years ago, miRNAs have been recognized as molecules that function specifically in post-transcriptional control in most eukaryotic genomes (6). However, their action in BPH has been poorly explored to date. In the present study we found an overexpression of miR-143 and miR-145 respectively in 62.5% and 73.8% of the cases compared to normal prostatic tissue. As these miRNAs target a number of transcriptional factors involved in the differentiation and proliferation of smooth muscle cells (10), the major reason for investigating these specific miRNAs was their considerable increase in smooth muscle fibers, which are known to play an important role in BPH physiopathology (12). BPH involves high cell proliferation; thus, the overexpression of these miRNAs may be related to the cellular proliferation found in BPH.

In cardiac muscle, miR-143 and miR-145 can regulate the quiescent versus proliferative phenotype in smooth muscle cells. Moreover, miR-145 is instrumental in defining the fate of smooth muscle and is associated with a contractile phenotype (13). Our hypothesis is that these miRNAs may function in both increased stromal proliferation in prostatic tissue and in the induction of a contractile phenotype, which has been shown in BPH. There are several reports in the literature that show the involvement of miR-143 and miR-145 in modulating cellular activities that are important in cardiac morphogenesis (13), in maintaining aortic smooth muscle cells (14), and in modulating the response of cytoskeletal smooth muscle cells to injury (15). The strong expression of miR-143 and miR-145 in human corneal epithelium has been linked to the regulation and formation of epithelium and to maintaining its integrity (16).

Growth factors are recognized as potent stimulators of cell proliferation in the normal prostate and in BPH, and this important group of peptides and their cellular receptors are found at higher amounts in BPH specimens when compared to normal prostates. The growth factor TGF-β uses distinct pathways for the transcriptional activation of miR-143 and miR-145 in smooth muscle cells in the human coronary artery (17), potentially explaining the overexpression of these miRNAs found in our work.

The expression of miR-143 and miR-145 is reduced in cells of colorectal tumor origin when compared to normal colon epithelia (11). The present study also identified KRAS as a protein target of these miRNAs and revealed that the main mediators of the oncosuppression by miR-143 and miR-145 are genes belonging to the growth factor receptor-mitogen-activated protein kinase network and to the p53 signaling pathway. We can infer that overexpression of these miRNAs appears to be only observed in normal tissues, suggesting that these miRNAs are associated with processes of neoplastic transformation.

ERK5 is a member of the MAPK superfamily and is involved in the regulation of several cellular processes, including differentiation, proliferation, and survival (18). We found ERK5 to be underexpressed in 59.4% of the cases, and the expression of ERK5 protein to be decreased in BPH samples compared to normal tissue, a fact that may be related to miR-143 overexpression. In vitro studies should be conducted to confirm this regulation in BPH specimens. However, these results are in contrast with other reports in the literature showing an overactivity of ERK5 in BPH (19).

The overexpression of miR-143 and the decreased expression of ERK5 have been correlated to the decreased cell proliferation in prostate cancer cell lines (20). However, in the recent work of Ahmad et al (21), the loss of miR-143 expression was associated with increased ERK5 expression in prostate cancer.

Despite the decreases in ERK5 gene and protein expression in most cases of BPH, we found an increased protein expression in prostates greater than 60 grams when compared to smaller prostates (p=0.019). The presence of the ERK5 protein has been associated with the stimulation of proliferation in prostate cancer, which may also be reflected in our results, since the presence of this protein allows the activation of factors related to cell growth (22). Our results demonstrate that this signaling pathway may be important in the pathophysiology of BPH.

The KRAS gene triggers many signal transduction pathways, and we found an overexpression of both the KRAS gene and protein in 79.5% of the cases, with means of 2.41 and 4312.2, respectively. We also observed large differences in protein expression levels when we compared BPH and normal prostatic tissues (p=0.06). The protein product of the normal KRAS gene may be performing essential functions in normal tissue signaling (23), and KRAS can be activated in response to various extracellular signals, mainly by growth factors and cytokines. As mentioned above, growth factors are found in greater amounts in hyperplastic glands and may trigger KRAS activation, as observed in our findings. Furthermore, there is a possibility that BPH could result from active immune cells (24) and cytokines that are produced in different stages under this condition. Given these observations, cytokines can also be responsible for KRAS activation in BPH. The activation of KRAS is responsible for activating receptor signals, such as Raf and PI3K; additionally, KRAS overexpression stimulates the PI3K pathway, which is associated with increased proliferation and decreased apoptosis in BPH animal models (25).

The MAP3K3 gene was found to be overexpressed in 61.5% of the cases, though the MAP3K3 protein was detected in 100% of the cases (means of 1.21 and 7461.7, respectively). MAP3K3 is a member of the MAP kinase signaling cascade and is responsible for directly activating ERK pathway components; however, this was not observed in our study, as ERK5 was found to be underexpressed. Nonetheless, the overexpression of KRAS may be related to MAP3K3 overexpression because the gene is responsible for the activation of members of the MAPK signaling pathway.

MAP3K3 plays a crucial role in angiogenesis and vasculogenesis. In 2000 Yang et al showed that MAP3K03 inactivation led to a strong disturbance in blood vessel development and early embryo death in mice (26). The overexpression of MAP3K3 and its protein product observed in our study may be responsible for the increased angiogenesis due to proliferative processes associated with BPH. Adrenoceptor antagonists such as prazozin, which inhibit angiogenesis, are routinely used for the treatment of BPH, thus demonstrating that this process is an important one in this disease, perhaps promoted by the activity of MAP3K3. Moreover, MAP3K3 overexpression has also been observed in human embryonic stem cells and is associated with cell maintenance and differentiation (27).

MAPKs play important roles in regulating immune responses and immune cell development in addition to activation, differentiation, and survival. The MAP3K3 protein is constitutively expressed in T lymphocytes (28), and T effector lymphocytes are found near the prostatic ducts approximately 6 times more frequently in men over 55 years old. This finding may indicate that an autoimmune phenomenon generated by some specific antigens appears in the prostate over time (24). As a result, the microenvironment surrounding the prostate epithelial cells would be flooded by lymphokines that can influence the local production of growth factors and angiogenesis in prostate tissue (29). Thus, MAP3K3 overexpression in T lymphocytes could contribute to this process and to the induction of angiogenesis. In accordance with these findings, we detected the MAP3K3 protein in all the BPH samples examined.

Conversely, MAP4K4 was found to be underexpressed in all samples (with a mean of 0.16), and the MAP4K4 protein was absent in 65.8% of the cases, with different means for BPH and normal tissues (2,827.3 vs 4,103.6, respectively p=0.041). This relationship demonstrates that this gene may be under the regulation of miR-145 and, consequently, of the mTOR pathway, which plays a central role in many cellular processes involved in cell growth, including smooth musculature (30). Our main hypothesis is that MAP4K4 underexpression, in this case controlled by miR-145, can fail to downregulate mTOR, which can lead to the irregular cell proliferation that is responsible for BPH.

Although the pathogenesis of BPH is not yet fully understood, the present study allows us to confirm that miRNAs may be involved in disease development. Further studies with other miRNAs are likely to provide important information for the understanding of this disease and the development of new potential therapies.

In conclusion, miR-143 and miR-145 are overexpressed in patients with BPH, and the latter of these miRNAs may act through the inhibition of MAP4K4. KRAS and MAP3K3 are overexpressed in patients with BPH. With respect to clinical parameters, ERK5 showed higher protein expression levels in patients with a larger prostate. Further functional analyses are necessary to better define the mechanisms of action and the pathways involved, together with these genes and proteins, in this regulation of the prostatic tissue.

Footnotes

Informed consent: All subjects provided informed consent to participate in the study and to allow the genetical analysis of their biological samples.

Financial support: This study was supported by FAPESP (Fundação de Amparo à Pesquisa do Estado de Sao Paulo) under protocol number 2010/50786-2.

Conflict of interest statements: The authors have declared that no conflict of interest exists.

Meeting presentation: AUA Annual Meeting 2011, AUA Annual Meeting 2012, XXXIV Congresso Brasileiro de Urologia, XXVIII Congresso Brasileiro de Patologia and XXVIII Congreso de la Sociedad Latinoamericana de Patologia.

References

Bianchi-Frias

Vakar-Lopez

Coleman

Plymate

Reed

Nelson

The effects of aging on the molecular and cellular composition of the prostate microenvironment.

PSPLoS One. 2010 5(9) 12501.

Schauer

Rowley

The functional role of reactive stroma in benign prostatic hyperplasia.

Differentiation. 2011 824-5 200–210.

Franco-Salinas

de la Rosette

JJMHC

Michel

Pharmacokinetics and pharmacodynamics of tamsulosin in its modified-release and oral controlled absorption system formulations.

Clin Pharmacokinet. 2010 49(3) 177–188.

Tang

Yang

Etiopathogenesis of benign prostatic hypeprlasia.

Indian J Urol. 2009 25(3) 312–317.

Pillai

Bhattacharyya

Artus

Inhibition of translational initiation by Let-7 MicroRNA in human cells.

Science. 2005 309(5740) 1573–1576.

Lee

Feinbaum

Ambros

The

elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14.

Cell. 1993 75(5) 843–854.

Reinhart

Slack

Basson

The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans.

Nature. 2000 403(6772) 901–906.

Ambros

The functions of animal microRNAs.

Nature. 2004 431(7006) 350–355.

Chen

Callis

Wang

microRNAs and muscle disorders.

J Cell Sci. 2009 122Pt 1 13–20.

10.

Cordes

Sheehy

White

miR-145 and miR-143 regulate smooth muscle cell fate and plasticity.

Nature. 2009 460(7256) 705–710.

11.

Pagliuca

Valvo

Fabrizi

Analysis of the combined action of miR-143 and miR-145 on oncogenic pathways in colorectal cancer cells reveals a coordinate program of gene repression.

Oncogene. Oncogene. 2013Oct 32(40) 4806–13.

12.

Chagas

Babinski

Costa

Stereological analysis of histologic components in transition zone of normal and hyperplastic human prostates.

Br J Urol. 2001; 27: 26–31.

13.

Boettger

Beetz

Kostin

Acquisition of the contractile phenotype by murine arterial smooth muscle cells depends on the Mir143/145 gene cluster.

J Clin Invest. 2009 119(9) 2634–2647.

14.

Elia

Quintavalle

Zhang

The knockout of miR-143 and -145 alters smooth muscle cell maintenance and vascular homeostasis in mice: correlates with human disease.

Cell Death Differ. 2009 16(12) 1590–1598.

15.

Xin

Small

Sutherland

MicroRNAs miR-143 and miR-145 modulate cytoskeletal dynamics and responsiveness of smooth muscle cells to injury.

Genes Dev. 2009 23(18) 2166–2178.

16.

Lee

Teng

Wong

MicroRNA-145 regulates human corneal epithelial differentiation.

PLoS ONE. 2011 6(6) e21249.

17.

Long

Miano

Transforming growth factor-beta1 (TGF-beta1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells.

J Biol Chem. 2011 286(34) 30119–30129.

18.

Nishimoto

Nishida

MAPK signalling: ERK5 versus ERK1/2.

EMBO Rep. 2006 7(8) 782–786.

19.

Clapé

Fritz

Henriquet

miR-143 interferes with ERK5 signaling, and abrogates prostate cancer progression in mice.

PLoS ONE. 2009 4(10) e7542.

20.

Zhang

Duan

The proliferative effect of estradiol on human prostate stromal cells is mediated through activation of ERK.

Prostate. 2008 68(5) 508–516.

21.

Ahmad

Singh

Yang

Mir143 expression inversely correlates with nuclear ERK5 immunoreactivity in clinical prostate cancer.

Br J Cancer. 2013 108(1) 149–54.

22.

Mehta

Jenkins

McCarthy

MEK5 overexpression is associated with metastatic prostate cancer, and stimulates proliferation, MMP-9 expression and invasion.

Oncogene. 2003 22(9) 1381–1389.

23.

Kranenburg

The KRAS oncogene: past, present, and future.

Biochim Biophys Acta. 2005 1756(2) 81–82.

24.

Theyer

Kramer

Assmann

Phenotypic characterization of infiltrating leukocytes in benign prostatic hyperplasia.

Lab Invest. 1992 66(1) 96–107.

25.

Jin

Wang

Peng

Yang

[Effect of PI3K/AKT inhibitor on benign prostate hyperplasia and its mechanism: an experimental study].

Zhonghua Nan Ke Xue. 2010 16(12) 1068–1075.

26.

Yang

Boerm

McCarty

Bucana

Fidler

Zhuang

Mekk3 is essential for early embryonic cardiovascular development.

Nat Genet. 2000 24(3) 309–13.

27.

Son

Kim

Han

Expression profiles of protein tyrosine kinase genes in human embryonic stem cells.

Reproduction Research. 2008 136(4) 423–432.

28.

Wang

Zhang

Chen

MEKK3 regulates IFN-gamma production in T cells through the Rac1/2-dependent MAPK cascades.

J Immunol. 2011 186(10) 5791–5800.

29.

Lucia

Lambert

Growth factors in benign prostatic hyperplasia: basic science implications.

Curr Urol Rep. 2008 99(4) 272–278.

30.

Guntur

Guilherme

Xue

Chawla

Czech

Map4k4 negatively regulates peroxisome proliferator-activated receptor (PPAR) gamma protein translation by suppressing the mammalian target of rapamycin (mTOR) signaling pathway in cultured adipocytes.

J Biol Chem. 2010 285(9) 6595–6603.

MicroRNAs 143 and 145 May be Involved in Benign Prostatic Hyperplasia Pathogenesis through Regulation of Target Genes and Proteins

Abstract

Objectives

Methods

Results

Conclusions

Introduction

Materials and Methods

Patients

Isolation of RNA and miRNA

Analysis of gene expression

Western blotting

Statistical Analysis

Results

Discussion

Footnotes

References